The invention also discloses application of PARP inhibitor PJ34 in preparation of anti-fish rhabdovirus products

Abstract

The invention discloses an application of a PARP inhibitor PJ34 in preparation of an anti-fish rhabdovirus product. The invention provides an application of a PARP inhibitor PJ34 or a derivative thereof or a pharmaceutically acceptable salt thereof or a substance taking the PARP inhibitor PJ34 or the derivative thereof or the pharmaceutically acceptable salt thereof as an active ingredient in preparation of an anti-fish rhabdovirus product. In the invention, a plurality of PARP inhibitors are screened, and results show that the PARP inhibitor PJ34 can inhibit mRNA replication of IHNV, VHSV andSVCV viruses in cells and reduce titer (TCID50) of the IHNV, the VHSV and the SVCV viruses at the same time; and the inhibition effect of the PJ34 on the IHNV, the VHSV and the SVCV shows a dose-dependent relationship. The PARP inhibitor PJ34 is expected to become a novel drug for resisting fish rhabdovirus.

Description

technical field [0001] The invention relates to the field of aquaculture, in particular to the application of PARP inhibitor PJ34 in the preparation of anti-fish rhabdovirus products. Background technique [0002] Since 2010, the output of the world's aquaculture industry has grown rapidly. However, the spread of infectious diseases has seriously affected the healthy and sustainable development of aquaculture. The research and application of preventive and therapeutic drugs have become an urgent need for the aquaculture industry. [0003] Infectious hematopoietic necrosis (IHN) is one of the major diseases endangering salmon and trout farming in the world. It is caused by infectious hematopoietic necrosis virus (IHNV), which is a serious threat to 1. Acute infectious diseases of trout can usually cause 80%-100% mortality depending on the fish species, fish age, virus strains and breeding environment. [0004] Viral haemorrhagic septicaemia (VHS) is an infectious disease mai...

AI Technical Summary

Problems solved by technology

Although inactivated vaccines and attenuated vaccines have played a good role in the prevention of IHNV, VHSV and SVCV, they are easy to cause residues in the breeding environment during their use, and may lead to pathogen resistance and virus mutations. form

In contrast, nucleic acid vaccines are relatively safe, but the currently used nucleic acid vaccines use CMV as the promoter to express the target antigen gene. Since the CMV promoter is derived from human pathogens, nucleic acid vaccines are dangerous to humans. security possibilities, which severely limits its application

Images